Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma, Metastatic Interventions:   Drug: ESK981;   Drug: Nivolumab Sponsors:   University of Michigan Cancer Center;   VA Ann Arbor Healthcare System Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials